The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Article first published online: 28 JUL 2010
Copyright © 2010 Movement Disorder Society
Volume 25, Issue 12, pages 1818–1822, 15 September 2010
How to Cite
Simon, K. C., Gao, X., Chen, H., Schwarzschild, M. A. and Ascherio, A. (2010), Calcium channel blocker use and risk of Parkinson's disease. Mov. Disord., 25: 1818–1822. doi: 10.1002/mds.23191
Potential conflict of interest: Nothing to report.
Financial disclosures: Nothing to report.
- Issue published online: 8 SEP 2010
- Article first published online: 28 JUL 2010
- Manuscript Accepted: 23 MAR 2010
- Manuscript Revised: 18 DEC 2009
- Manuscript Received: 15 JUL 2009
- calcium channel blockers;
- Parkinson's disease;
We investigated whether the use of calcium channel blockers (CCBs) was associated with a reduced risk of Parkinson's disease (PD) in two large prospective cohorts: the Nurses' Health Study (NHS) and Health Professionals' Follow-Up Study (HPFS). Cox proportional hazards models were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) to assess the association between use of CCBs and risk of PD adjusting for potential confounders. We identified 514 incident cases of PD during follow-up. No association between baseline use of CCBs (RR = 1.18, 95% CI: 0.73–1.92), frequency of use or duration of use of CCBs and PD risk was observed (P > 0.2 for all). These findings do not support a role for CCBs in providing neuroprotection against development of PD. © 2010 Movement Disorder Society